Skip to content

Safety and Efficacy of the Addition of Morphine Chloride to a Low Dose of Bupivacaine as Intradural Anaesthetic for the Removal Surgery of the Hemorrhoids

Assessment of the Analgesic Efficacy of Morphine Chloride in Addition to a Low Dose Solution of Spinal Anaesthetic in Hemorrhoidectomy Compared to a Standard Dose of Spinal Local Anaesthetic. Simple Blind, Randomized, With Blinded Evaluation by Third Parties Clinical Trial.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02046772
Enrollment
63
Registered
2014-01-28
Start date
2012-03-31
Completion date
2014-03-31
Last updated
2016-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Remove of Hemorrhoids

Keywords

hemorrhoidectomy, analgesia, anaesthetic, bupivacaine, morphine chloride

Brief summary

A single blind, randomized, with blinded evaluation by third parties clinical trial is carried out to assess the analgesic efficay of the addition of morphine chloride to a low dose solution of spinal local anaesthetic compared to a standard dose spinal anaesthetic in the haemorrhoid surgery. The objective of this clinical trial is to assess if the experimental treatment is as efficacy as the standard treatment in the anesthetic and analgesic effects with less side effects, greater and earlier mobility after surgery and shortened the hospitalization.

Detailed description

DESIGN OF THE TRIAL: A multicentre, randomized, single-blind, with masked evaluationby third parties clinical trial. The Clinical Pharmacology Unit will perform a permuted blocks randomization scheme for each of the two hospitals participating in the trial. The result of this randomization will be kept in this unit and will not be accessible to investigators. Investigators will receive a series of opaque sealed envelopes with a number corresponding to the order of entry of the patients into the trial. When the patient is in the operating room, investigators must open the envelope which contains the group of treatment assigned to that patient. The patient will not know in which intervention group is included. Investigator who performs the spinal puncture and investigator who collects the data and performs the evaluation will no be the same person. This will allow a blind evaluation. OBJECTIVES: Main objective: To evaluate whether the addition of morphine chloride to a low dose solution of local intradural anaesthetic in patients undergoing hemorrhoids surgery produces an anaesthetic efficacy comparable to that produced by a standard dose of local intradural anaesthetic and an improvement of postoperative analgesic efficacy. Secondary objectives: * Earlier mobilization of the patient. * Minor adverse effects. * A shorter hospital stay of the patient. TREATMENTS: Two groups of treatment will be formed, experimental and comparator. The experimental group will receive 3mg of Bupivacaine with addition of 50 micrograms of Morphine Chloride. The comparator group will receive 5 mg of Bupivacaine. RESCUE TREATMENTS If necessary before surgery, midazolam will be administered from 0.02 to 0.05 mg / kg intravenous (IV) depending on clinical response and after the patient is set in the surgical position, if necessary, an intravenous infusion of propofol will be administered at 0.5 - 2mg / kg / h. Sedative drugs with analgesic effects as opioids, ketamine, etc, will be avoided to not interfere with the main analgesic study assessment. After surgery and during the hospitalization stay the rescue analgesia treatment will be administered only on demand. The rescue treatment allowed by protocol will be an intravenous administration of dexketoprofen up to 50 mg / 8 h and if insufficient, a rescue of 3 mg of morphine chloride will be administered. If morphine chloride is received, these patients will be recorded in the case report forms as inefficacy of the treatment. At home, after discharge, patients will receive rescue analgesia with capsules of dexketoprofen 25 mg / 8 h. (up to 75 mg a day). SAMPLE SIZE: 66 patients ( 33 patients in the experimental group and 33 patients in the control group) EFFICACY ASSESSMENT Pain will be assessed using a visual analog scale (VAS from 0 to 10) at the beginning and end of surgery, at the arrival of resuscitation unit, after 10 and 30 minutes after arrival, during hospitalization stay out of the resuscitation unit and daily at home after discharge. Doses required of rescue analgesia and hospitalization time will be recorded. SAFETY ASSESSMENT Basic monitoring as usual will be perfomed in the surgery room. Motor blockage will be assessed using the modified Bromage scale as follows: 1 = complete motor blocking, 2 = able to move feet only, 3 = patient move the feet and bend the knee, 4 = straight leg raises \<30 ° or \> 30 ° but not against resistance, 5 = lifts leg\> 30 ° against resistance. This measure will be made after surgery in the surgery room and at the arrival and at one hour after resuscitation unit admission. All the Adverse events will be reported.

Interventions

DRUGBupivacaine low dose

A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural

DRUGBupivacaine standard dose

Single intradural standard dose of bupivacaine

A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural

Sponsors

Spanish Agency of Medicines and Health Products
CollaboratorOTHER_GOV
Spanish Health Ministry
CollaboratorUNKNOWN
Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Patients undergoing hemorrhoidectomy. * Age between 18 and 64. * Both gender * ASA I to III. * With indication for spinal block. * People capable to grant the informed consent.

Exclusion criteria

* Patients with allergies to the study drugs. * Patients with any contraindication for performing a spinal technique (coagulation disorders, fever, intracraneal hypertension, abscess in the puncture site, etc..). * Patients with previous neurological disorders. * Pregnant women. * Women who may be pregnant and do not have a negative pregnancy test. * Breastfeeding women. * Patients with uncapable to give informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Measurement of Time to Start the Anaesthetic EffectFirst 20 minutes between administration and beginning of surgeryTo compare whether the addition of morphine chloride to a low dose intradural solution of the local anaesthetic bupivacaine is as effective as an administration of a single dose of bupivacaine.
Measurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.Up to 72 hours from the end of the surgery in the hospital stay and during the next 7 days at home, after dischargeTo compare whether the addition of morphine chloride to a low dose solution of bupivacaine and improves the analgesic treatment than a single administration of bupivacaine.

Secondary

MeasureTime frameDescription
Greater and Earlier Mobilization Measured by Bromage Scale.During the first 24 hours after surgery and at the entry and exit of the resuscitation unitTo assess whether the administration of morphine chloride in addition to a low dose solution of local intradural anaesthetic (bupivacaine) improves the mobilization of the patients after surgery more than the single intradural administration of bupivacaine. Total Score in the Bromage Scale goes from 1 to 5, where: 1: complete motor blocking - 2: capable to move the feet - 3: moves the feet and bends the knee - 4: raise the leg straight more or less than 30 degrees but no against resistance - 5: raise the leg straight more than 30 degrees against resistance (no motor blocking)
Number of Adverse EventsUp to 72 hours from the intervention and the hopitalary stay and during the next 7 days after dischargeTo assess if the experimental treatment causes less, equal or more adverse events than the comparator treatment.
Time of HospitalizationUp to 72 hours after the interventionTo see if the hospitalization time is shortened or not by the experimental treatment.

Countries

Spain

Participant flow

Participants by arm

ArmCount
Bupivacaine + Morphine Chloride
People in this arm will receive treatment with morphine chloride (50 mcgr) in addition to a low dose solution of the local intradural anaesthetic bupivacaine (3mg). Bupivacaine low dose: A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural. Morphine Chloride: A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural.
30
Bupivacaine Standard Dose
People in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine (5mg). Bupivacaine standard dose: Single intradural standard dose of bupivacaine.
33
Total63

Baseline characteristics

CharacteristicBupivacaine + Morphine ChlorideBupivacaine Standard DoseTotal
Age, Continuous45.8 years
STANDARD_DEVIATION 10.5
51.3 years
STANDARD_DEVIATION 10.8
48.7 years
STANDARD_DEVIATION 10.9
ASA
ASA I
7 participants8 participants15 participants
ASA
ASA II
22 participants25 participants47 participants
ASA
ASA III
1 participants0 participants1 participants
BMI25.1 Kg*m^-2
STANDARD_DEVIATION 3.3
27.2 Kg*m^-2
STANDARD_DEVIATION 4
26.2 Kg*m^-2
STANDARD_DEVIATION 3.9
Duration of surgery28 minutes
STANDARD_DEVIATION 11.1
20.4 minutes
STANDARD_DEVIATION 9.2
24 minutes
STANDARD_DEVIATION 10.8
Need of pre-surgery sedation
No
7 participants10 participants17 participants
Need of pre-surgery sedation
Yes
23 participants23 participants46 participants
Number of haemorrhoidal packs removed
1 haemorrhoidal pack
8 participants12 participants20 participants
Number of haemorrhoidal packs removed
2 haemorrhoidal packs
12 participants13 participants25 participants
Number of haemorrhoidal packs removed
3 haemorrhoidal packs
8 participants8 participants16 participants
Number of haemorrhoidal packs removed
Unavailable
2 participants0 participants2 participants
Region of Enrollment
Spain
30 participants33 participants63 participants
Sex: Female, Male
Female
13 Participants13 Participants26 Participants
Sex: Female, Male
Male
17 Participants20 Participants37 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
10 / 304 / 33
serious
Total, serious adverse events
0 / 300 / 33

Outcome results

Primary

Measurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.

To compare whether the addition of morphine chloride to a low dose solution of bupivacaine and improves the analgesic treatment than a single administration of bupivacaine.

Time frame: Up to 72 hours from the end of the surgery in the hospital stay and during the next 7 days at home, after discharge

ArmMeasureGroupValue (MEAN)Dispersion
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS at the enter in the reanimation unit0.03 units on a scaleStandard Deviation 0.1
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS after 10 minutes in reanimation unit0 units on a scaleStandard Deviation 0
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS after 30 minutes in reanimation unit0.06 units on a scaleStandard Deviation 0.3
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 1 after surgery1.5 units on a scaleStandard Deviation 1.2
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 2 after surgery3.8 units on a scaleStandard Deviation 2.8
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 3 after surgery3.7 units on a scaleStandard Deviation 2.7
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 4 after surgery3.6 units on a scaleStandard Deviation 2.6
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 5 after surgery3.6 units on a scaleStandard Deviation 2.3
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 6 after surgery3.2 units on a scaleStandard Deviation 2.6
Bupivacaine + Morphine ChlorideMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 7 after surgery2.5 units on a scaleStandard Deviation 2.3
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 5 after surgery4 units on a scaleStandard Deviation 2.2
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS at the enter in the reanimation unit0.15 units on a scaleStandard Deviation 0.7
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 3 after surgery4.5 units on a scaleStandard Deviation 2.3
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS after 10 minutes in reanimation unit0.3 units on a scaleStandard Deviation 1
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 7 after surgery3 units on a scaleStandard Deviation 2.2
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS after 30 minutes in reanimation unit0.72 units on a scaleStandard Deviation 1.5
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 4 after surgery4.4 units on a scaleStandard Deviation 2.3
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 1 after surgery3.3 units on a scaleStandard Deviation 2.2
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 6 after surgery3.5 units on a scaleStandard Deviation 2.3
Bupivacaine Standard DoseMeasurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.VAS day 2 after surgery4 units on a scaleStandard Deviation 2.5
Primary

Measurement of Time to Start the Anaesthetic Effect

To compare whether the addition of morphine chloride to a low dose intradural solution of the local anaesthetic bupivacaine is as effective as an administration of a single dose of bupivacaine.

Time frame: First 20 minutes between administration and beginning of surgery

ArmMeasureGroupValue (MEAN)Dispersion
Bupivacaine + Morphine ChlorideMeasurement of Time to Start the Anaesthetic EffectTime to sensitive blocking2.1 minutesStandard Deviation 1.8
Bupivacaine + Morphine ChlorideMeasurement of Time to Start the Anaesthetic EffectTime to motor blocking7.7 minutesStandard Deviation 5.9
Bupivacaine Standard DoseMeasurement of Time to Start the Anaesthetic EffectTime to sensitive blocking1.6 minutesStandard Deviation 1.5
Bupivacaine Standard DoseMeasurement of Time to Start the Anaesthetic EffectTime to motor blocking4.7 minutesStandard Deviation 3.3
Secondary

Greater and Earlier Mobilization Measured by Bromage Scale.

To assess whether the administration of morphine chloride in addition to a low dose solution of local intradural anaesthetic (bupivacaine) improves the mobilization of the patients after surgery more than the single intradural administration of bupivacaine. Total Score in the Bromage Scale goes from 1 to 5, where: 1: complete motor blocking - 2: capable to move the feet - 3: moves the feet and bends the knee - 4: raise the leg straight more or less than 30 degrees but no against resistance - 5: raise the leg straight more than 30 degrees against resistance (no motor blocking)

Time frame: During the first 24 hours after surgery and at the entry and exit of the resuscitation unit

ArmMeasureGroupValue (MEAN)Dispersion
Bupivacaine + Morphine ChlorideGreater and Earlier Mobilization Measured by Bromage Scale.Bromage at the exit of surgery4 units on a scaleStandard Deviation 1.3
Bupivacaine + Morphine ChlorideGreater and Earlier Mobilization Measured by Bromage Scale.Bromage at the enter in the reanimation unit4.1 units on a scaleStandard Deviation 1.1
Bupivacaine + Morphine ChlorideGreater and Earlier Mobilization Measured by Bromage Scale.Bromage at the exit of the reanimation unit4.7 units on a scaleStandard Deviation 0.4
Bupivacaine Standard DoseGreater and Earlier Mobilization Measured by Bromage Scale.Bromage at the exit of surgery3.7 units on a scaleStandard Deviation 1
Bupivacaine Standard DoseGreater and Earlier Mobilization Measured by Bromage Scale.Bromage at the enter in the reanimation unit3.8 units on a scaleStandard Deviation 1
Bupivacaine Standard DoseGreater and Earlier Mobilization Measured by Bromage Scale.Bromage at the exit of the reanimation unit4.8 units on a scaleStandard Deviation 0.3
Secondary

Number of Adverse Events

To assess if the experimental treatment causes less, equal or more adverse events than the comparator treatment.

Time frame: Up to 72 hours from the intervention and the hopitalary stay and during the next 7 days after discharge

ArmMeasureGroupValue (NUMBER)
Bupivacaine + Morphine ChlorideNumber of Adverse EventsPruritus2 participants
Bupivacaine + Morphine ChlorideNumber of Adverse EventsUrinary retention7 participants
Bupivacaine + Morphine ChlorideNumber of Adverse EventsNausea/Vomits0 participants
Bupivacaine + Morphine ChlorideNumber of Adverse EventsFever1 participants
Bupivacaine Standard DoseNumber of Adverse EventsFever0 participants
Bupivacaine Standard DoseNumber of Adverse EventsPruritus0 participants
Bupivacaine Standard DoseNumber of Adverse EventsNausea/Vomits1 participants
Bupivacaine Standard DoseNumber of Adverse EventsUrinary retention3 participants
Secondary

Time of Hospitalization

To see if the hospitalization time is shortened or not by the experimental treatment.

Time frame: Up to 72 hours after the intervention

ArmMeasureGroupValue (NUMBER)
Bupivacaine + Morphine ChlorideTime of Hospitalization1 day of hospitalization26 participants
Bupivacaine + Morphine ChlorideTime of Hospitalization2 days of hospitalization3 participants
Bupivacaine + Morphine ChlorideTime of Hospitalization3 days of hospitalization1 participants
Bupivacaine Standard DoseTime of Hospitalization1 day of hospitalization30 participants
Bupivacaine Standard DoseTime of Hospitalization2 days of hospitalization2 participants
Bupivacaine Standard DoseTime of Hospitalization3 days of hospitalization1 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026